patie nts unde rwent consecutive Orthotopic Live r Transplantation (O LTx) at the Unive rsity of Pittsburgh. Forty of these patie nt' s had concomitant splene ctomy with O LTx. These patie nts were compare d to 147 randomly selected O LTx patie nts without sple nectomy within the same time pe riod. O ne-year patie nt and graft survival (PS and GS) were lowe r in splene ctomize d (Splx) patie nts compare d to nonsple nectomized (non-Splx) patie nts (59% vs 86% PS, 55% vs 80% GS, re spective ly) . O ne-month and one -year patie nt mortality in the Splx group was highe r than in the non-splx patie nts (20% vs 3.4% , P , 0.001 for one month; 40% vs 14.3% , P 5 0.003 for one ye ar, respe ctively) . One -month and one -ye ar se psis-re late d mortality was also high in Splx patie nts (17.5% vs 2.7% , P 5 0.0022, for one month, and 30% vs 11.5% , P 5 0.0043, for one ye ar, respe ctively) . We conclude that concomitant sple ne ctomy with O LTx has a signi® cantly highe r patie nt mortality mainly due to its septic complications and, at pre se nt, unle ss there is a speci® c indication for a splene ctomy, the routine addition of this proce dure to live r allograft surge ry would not be re comme nde d.
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There are contradictory re ports re garding the e ffe ct of sple ne ctomy on allograft re jection following transplantation (1± 14) . Some have re porte d a bene ® cial e ffect of splene ctomy eithe r pre -or pe ritransplantation (1± 4, 6, 7, 9, 10) and have attribute d this bene ® t to a reduction in antibody production (1, 2) or improve d leukocyte count and there fore tole rance to azathioprine (AZA) (3, 4, 6, 10, 15) . O the rs have shown no be ne® t, discouraging the routine use of this proce dure because of its pote ntially le thal complications due to de laye d infe ction and thromboe mbolic e vents (5, 8, 13, 16) .
Be cause of the ne arly unive rsal pre se nce of pancytope nia in se riously ill live r candida te s and conse que nt proble ms with AZ A dosing, concom itant sple ne ctom y was pe rforme d with live r transplantation in most he patic re cipie nts until 1980. With the adve nt of nonm ye lotoxic age nts, such as cyclosporine , the routine use of this fre que ntly dif® cult adjuvant proce dure was discontinue d and is rare ly pe rforme d today.
The obje ctive of our study was to e xamine the role of sple ne ctomy in live r transplantation and to ide ntify the pote ntial hazards associate d with this procedure in mode rn immunosupp re ssive re gimens.
MATERIALS AND METHODS
The records of 1466 patie nts who underwent O LTx at the Unive rsity of Pittsburgh betwee n January 1987 and O ctober 1991 we re reviewed. Ninete en patients undergoing upper abdominal e xe nte ration and thirteen patie nts with splenectomy (Splx) following OLTx we re excluded from this study. From the remaining 1434 patie nts, we identi® e d 40 (2.8% ) who had undergone combined OLTx 1 Splx. The course of the se patients was compared to 150 randomly selected non-Splx patie nts from the same transplant period. The sample size was calculated to ensure that a 25% or more diffe rence in mortality could be dete cte d betwee n the Splx and the non-Splx group using methods of unequal group sizes (17) . The records of three patie nts could not be obtained, therefore, the remaining 147 patie nts serve d as the non-Splx group. The two groups we re comparable with respect to donor and recipient age , sex, HLA-A, B, and DR mismatch, etiology of liver disease, UNOS status, cold ischemic time , plate let count, and immunosuppressive regimen (Tables 1 and 2 ) . Although there we re more positive lymphocytotoxic cross-matches in the study (Splx) group, the diffe rence was not statistically signi® cant (Tables 1 and  2 ) . The two groups we re not comparable with respect to the amount of perioperative blood transfusion.
Indications for splenectomy included positive lymphocy- Splx could not be dete rmined in the retrospective review ( Table 3 ).
The two groups we re analyze d with respect to patie nt and graft survival, as we ll as biopsy-proven acute allograft rejection within 30 days of transplantation. 
Statis tical Analys is. The results for continuous variables
are presente d as means 6 SD and for categorical variables as proportions. The standard two-sample t te st was used to test the diffe rence betwe en group me ans, while diffe rences in proportions were te ste d using Pearson's chi-square test or Fisher's exact te st. The Wilcoxon rank-sum te st, a nonparame tric e quivalent to the standard two-sample t test, was used for highly skewe d data (eg, amount of blood transfusions and plate let count). The odds ratio was calculated as an estimate of the relative risk of acute allograft rejection for Splx patie nts. An odds ratio . 1 indicates increase d risk, while an odds ratio , 1 indicates a protective e ffe ct of splenectomy. The Mante l-Haenszel procedure (18) was used to calculate an adjusted odds ratio based on lymphocytotoxic cross-match. A multivariate logistic regre ssion model was used to adjust the odds ratio for amount of blood transfusions. The 95% con® dence intervals were calculated using e ither the te st-base d procedure of Mie ttine n or Woolf's method (18) .
Patient survival was calculated from the date of OLTx until death, and graft survival from the date of O LTx until retransplantation or patie nt death. Survival curves we re generate d using the Kaplan-Me ier (product-limit) me thod and we re compare d using the ge ne ralize d Wilcoxon (Breslow) te st. All te sts we re two-taile d. P , 0.05 was considered statistically signi® cant. All analyses we re performed using SPSS for Windows software.
RESULTS

Patien t Su rvival.
With a minimum follow-up of one ye ar (median 35, range 12± 17 months) , the one -ye ar patie nt survival was 60% (24/40) in the Splx group vs 86% (126/147) in the non-Splx group (P 5 0.001) , a disparity that was alre ady signi® cant at 30 days (P 5 0.001) (Figure 1 ).
In the Splx group, e ight patie nts die d within 30 days of O LTx (8/40, 10% ) compare d to ® ve in the non-Splx group (5/147, 3% , P , 0.0001) . Four of the eight de aths were in patie nts with a positive cross-match (4/10, 40% ) and the othe r four in patie nts with negative cross-match (4/28, 14% , P 5 0.093) ( Table 3 ).
The one -year mortality base d on positive cross-match was 60% (6/10) in the Splx group and 22% (5/23) in the non-Splx group (P 5 0.0037) . The one -ye ar mortality base d on ne gative cross-match was 36% (10/28) in the Splx group and 12% (15/121) in the non-Splx group (P 5 0.005) .
Seve n of the e ight deaths in the Splx group during the ® rst month (7/40, 17.5% ) as well as 12 of the 16 by the end of the ® rst ye ar (12/40, 30% ) were due primarily to sepsis compare d to 4/147 (2.7% , P 5 0.0022) and 17/147 (11.6% , P 5 0.0043) , in the nonSplx group, respectively. Thre e of the 40 (7.5% ) patie nts in the Splx group, including two cross-match-positive patie nts, unde rwent retransplantation within 30 days of O LTx because of e ithe r primary nonfunction (PNF, N 5 1) or he patic artery thrombosis (HAT, N 5 2). One more patie nt was re transplante d afte r 30 days, for a total incide nce of 10% . Two (50% ) of the four atte mpts succee ded. Fourte e n (9.5% ) patie nts in the non-Splx group also unde rwent re transplantatio n, including three with a positive cross-match live r. Eight (57% ) were succe ssful.
Graft Su rvival. With the e quivale nt rate of succe ssful retransplantation, the graft survival curves of the Splx and non-Splx groups were both 5% lower than patie nt survival, and similar at all time points. Graft survival for Splx at one month was 78% vs 93% for non-Splx (P 5 0.004) , and at one year was 55% vs 80% , re spectively (P 5 0.001) .
Mu ltivaria te An al ys is .
Using a multivaria te logistic re gre ssion analysis, Splx patie nts had a highe r risk of one ye ar mortality ( odds ratio 5 3.1, P 5 0.042) e ve n afte r adjustin g for se le cted base line re cipie nt and donor characte ristics. Howe ve r, this multivaria te analysis did not re ve al a signi® cant association be twe e n sple ne ctomy and graft failure at one ye ar. (Table 4) .
The Splx patie nts re ceive d signi® cantly more units of blood transfusion within one month of O LTx than non-Splx patie nts (Table 1) ; howe ver, in a multivariate logistic re gre ssion mode l, the rejection rate was not affe cted by the diffe rence in the total amount of blood transfusions (Table 5) .
DISCUSSION
The contribution of the sple e n as part of the immune re sponse to the transplante d graft is not clearly known (6, 19 ± 22) . The sple e n is not only the principle site of antibody synthe sis (6, 9, 23) , including speci® c alloantibodie s (22, 24 ± 26) , but also is a source of spe ci® c allore active host lymphocyte s (23) . It has bee n sugge sted that transie nt posttransplant migration of dendritic cells from the transplante d graft to the sple en may be responsible for initiation of graft re je ction (20) . On the contrary the sple en may play a major role in prolongation of graft survival in diffe re nt species (19, 21, 23 (4), also note d the advantage of sple nectomy but only in living relate d kidne y transplant patie nts. Two re ports in the 1980s also note d improve d patie nt and graft survival afte r sple nectomy (7, 8) . This is in contrast to se veral reports in the late 1980s that have cautione d against the routine use of sple nectomy in the renal transplant population (9, 10, 14, 16, 31, 32) .
This retrospe ctive study was unde rtake n be cause of the conce rn that de cisions to perform urge nt splene ctomy were made only for its historical justi® cation, name ly, the mitigation of the sple en-de pe nde nt antibody response (25, 26, 33± 35) , without attention to its hazards.
O ur concern about sple nectomy is similar to those that have bee n e xpe rie nced in re nal transplantation. A common the me in the e arlie r studie s was that sple nectomy appe ared to reduce the incide nce of e arly re je ction (4, 7, 8) . Similar to the re port by Megison (36) , Splx patie nts in our study had a significantly lowe r rate of re je ction compare d to non-Splx patie nts. This diffe re nce was still appare nt whe n rejection was strati® e d by positive and negative lymphocytotoxic cross-match (Table 3) . Patie nts with positive cross-matche s may pre sent with a clinical picture of antibody-me diate d re jection indistinguishable from PNF (37) ; howeve r, in our study none of the re transplante d patie nts for PNF had any histologically documented acute re je ction.
In our study sple ne ctomy was associate d with more blood transfusion. This extra transfusion re quire ment could be due to une xpe cted injury to the splee n or may be the re sult of pre forme d lymphocytotoxic antibody, which may le ad to exce ssive e limination of plate lets and subse que nt he morrhage (38) .
The most emphasize d risk of splene ctomy in the literature is the incre ase d susce ptibility to infe ction and thrombotic complications . Howe ver, in our opinion, the most se rious hazard of sple ne ctomy in a live r re cipie nt is aggravation of an alre ady dif® cult te chnical ope ration.
Neve rthe le ss, sple ne ctomy inde pe nde nt of othe r factors, including blood transfusion, has be e n associate d with an incre ase d risk of mortality ( 16) , with se psis as the le ading cause . O ur conce rn is re inforce d by the study re porte d he re and e mphasize s that the price of this e xtra surgical proce dure far outwe ighs any the ore tical be ne ® ts in O LTx patie nts. We conclud e that, base d on multiple lifethre ate ning risk factors assoc iate d with sple ne ctomy, concom itant sple ne ctomy with O LTx is not re comme nde d e xce pt in the rare occasion of unavoidable sple nic injury.
Inste ad of sple ne ctomy for patie nts with a positive cytotoxic cross-match, we now re comme nd intraope rative tre atme nt with a combination of highdose corticoste roids and prostaglandin E 1 . This tre atme nt is thought to ame liorate the diffuse inamm atory re sponse that is the basis of hype racute re je ction or its subclin ical variation s ( 39, 40) . Since institu ting this manage me nt policy in 1992 ( 41) , the e xtra hazard of live r transpl antation in the case of a positive crossmatch ( 40, 42) has be e n all but e liminate d (43) .
SUMMARY
The single center e xpe rience with sple nectomy in O LTx patie nts has be en re vie wed. One thousand four hundre d sixty-six patie nts had O LTx ove r a period of ® ve years. Forty of these patie nts had sple nectomy at the time of O LTx. The se patie nts were compare d to a randomly se le cted group of OLTx patie nts who did not have sple nectomy within the same time period. The re sults de monstrate that splx patie nts are at increase d risk for mortality, inde pe nde nt of othe r factors, mainly a due to incre ase d sepsis-re late d complications. 
